Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors

(2016) Sheri L. Moores et al.   CANCER RESEARCH

A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets

(2016) John J. Rhoden et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody

(2016) Songmao Zheng et al.   mAbs

XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer

(2016) Juergen M. Schanzer et al.   mAbs

Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments

(2016) Timothy J. Egan et al.   mAbs

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

(2016) Rizwan Romee et al.   Science Translational Medicine

Dicing up T-ALL

(2015) J. C. Aster   BLOOD

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

(2015) A. Rothe et al.   BLOOD

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

(2015) Emily C Piccione et al.   mAbs

Bispecific T-cell engagers for cancer immunotherapy

(2014) Amelia M Huehls et al.   IMMUNOLOGY AND CELL BIOLOGY

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Bispecific antibodies rise again

(2014) Ken Garber   NATURE REVIEWS DRUG DISCOVERY

The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature

(2013) Panagiotis Tsikouras et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies

(2013) Brian D. Harms et al.   METHODS

Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients

(2013) Katrin S. Reiners et al.   MOLECULAR THERAPY

Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition

(2012) Rebecca Croasdale et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

(2012) M. Klinger et al.   BLOOD

Soluble Monomeric IgG1 Fc

(2012) Tianlei Ying et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A recombinant triplebody with specificity for CD19 and HLA-DR mediates 
preferential binding to antigen double-positive cells by dual-targeting

(2012) Ingo Schubert et al.   mAbs

Dual targeting strategies with bispecific antibodies

(2012) Roland Kontermann   mAbs

Quantification of HER Expression and Dimerization in Patients’ Tumor Samples Using Time-Resolved Förster Resonance Energy Transfer

(2012) Alexandre Ho-Pun-Cheung et al.   PLoS One

Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties

(2012) R. Castoldi et al.   PROTEIN ENGINEERING DESIGN & SELECTION

B-Cell Maturation Antigen (BCMA) Activation Exerts Specific Proinflammatory Effects in Normal Human Keratinocytes and Is Preferentially Expressed in Inflammatory Skin Pathologies

(2011) Vassilia-Ismini Alexaki et al.   ENDOCRINOLOGY

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity

(2011) Jianying Dong et al.   mAbs

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting

(2010) Markus Kügler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Catumaxomab

(2010) Rolf Linke et al.   mAbs

Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial

(2010) Renier Brentjens et al.   MOLECULAR THERAPY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

(2010) Ralf Lutterbuese et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Natural killer cell cytotoxicity: how do they pull the trigger?

(2009) Nicola J. Topham et al.   IMMUNOLOGY

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro

(2008) M K Robinson et al.   BRITISH JOURNAL OF CANCER